Garsky VM - Search Results

1

Reversal of acid-induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2.

Karczewski J, Spencer RH, Garsky VM, Liang A, Leitl MD, Cato MJ, Cook SP, Kane S, Urban MO. Karczewski J, et al. Among authors: garsky vm. Br J Pharmacol. 2010 Oct;161(4):950-60. doi: 10.1111/j.1476-5381.2010.00918.x. Br J Pharmacol. 2010. PMID: 20860671 Free PMC article.

2

Prominent depressor response to endothelin in spontaneously hypertensive rats.

Winquist RJ, Bunting PB, Garsky VM, Lumma PK, Schofield TL. Winquist RJ, et al. Among authors: garsky vm. Eur J Pharmacol. 1989 Apr 12;163(1):199-203. doi: 10.1016/0014-2999(89)90420-2. Eur J Pharmacol. 1989. PMID: 2663529

3

Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.

Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ. Holahan MA, et al. Among authors: garsky vm. Pharmacology. 1991;42(6):340-8. doi: 10.1159/000138817. Pharmacology. 1991. PMID: 1946598

4

Rational design and synthesis of selective BACE-1 inhibitors.

Brady SF, Singh S, Crouthamel MC, Holloway MK, Coburn CA, Garsky VM, Bogusky M, Pennington MW, Vacca JP, Hazuda D, Lai MT. Brady SF, et al. Among authors: garsky vm. Bioorg Med Chem Lett. 2004 Feb 9;14(3):601-4. doi: 10.1016/j.bmcl.2003.11.061. Bioorg Med Chem Lett. 2004. PMID: 14741251

5

The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.

Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM. Garsky VM, et al. J Med Chem. 2001 Nov 22;44(24):4216-24. doi: 10.1021/jm0101996. J Med Chem. 2001. PMID: 11708923

6

Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus.

Shebuski RJ, Ramjit DR, Sitko GR, Lumma PK, Garsky VM. Shebuski RJ, et al. Among authors: garsky vm. Thromb Haemost. 1990 Dec 28;64(4):576-81. Thromb Haemost. 1990. PMID: 2084943

7

Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.

Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A, Freidinger RM, Garsky VM. Brady SF, et al. Among authors: garsky vm. J Med Chem. 2002 Oct 10;45(21):4706-15. doi: 10.1021/jm020139f. J Med Chem. 2002. PMID: 12361397

8

Echistatin is a potent inhibitor of bone resorption in culture.

Sato M, Sardana MK, Grasser WA, Garsky VM, Murray JM, Gould RJ. Sato M, et al. Among authors: garsky vm. J Cell Biol. 1990 Oct;111(4):1713-23. doi: 10.1083/jcb.111.4.1713. J Cell Biol. 1990. PMID: 2211834 Free PMC article.

9

Selective inhibition of factor Xa in the prothrombinase complex by the carboxyl-terminal domain of antistasin.

Mao SS, Przysiecki CT, Krueger JA, Cooper CM, Lewis SD, Joyce J, Lellis C, Garsky VM, Sardana M, Shafer JA. Mao SS, et al. Among authors: garsky vm. J Biol Chem. 1998 Nov 13;273(46):30086-91. doi: 10.1074/jbc.273.46.30086. J Biol Chem. 1998. PMID: 9804761 Free article.

10

Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.

Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan GA, Rosenblatt M. Fisher JE, et al. Among authors: garsky vm. Endocrinology. 1993 Mar;132(3):1411-3. doi: 10.1210/endo.132.3.8440195. Endocrinology. 1993. PMID: 8440195

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters